| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
21st Century Biochemicals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company.
We provide counseling, psychiatry, and targeted case management for children and adults without the long wait times throughout Kentucky. Discover our services today.
inVentiv Clinical Solutions is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.